SCHEMBL17229255

SCHEMBL17229255

CC(C)Cc1ccc(N(C)C2CCOC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELOVL1 Q9BW60 1/20 0.46
ACACB O00763 3/20 0.41
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PIK3CD O00329 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
ALDH1A1 P00352 1/20 0.34
KDM4E B2RXH2 2/20 0.34
RAB9A P51151 2/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
HSP90AA1 P07900 1/20 0.34
KMT2A Q03164 1/20 0.34
PARP14 Q460N5 1/20 0.33
USP1 O94782 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17232503 0.85 ELOVL1 (0.48) ELOVL1ACACBLMNASMN1; SMN2EGLN1
SCHEMBL17229265 0.82 SMN1; SMN2 (0.43) ACACBLMNASMN1; SMN2ALDH1A1JAK2
SCHEMBL19068763 0.80 ELOVL1 (0.47) ELOVL1ACACBLMNASMN1; SMN2EGLN1
SCHEMBL17229322 0.77 SLC6A2 (0.40)
SCHEMBL17254177 0.76 HTR2A (0.42) ALDH1A1KDM4EJAK2JAK1JAK3
SCHEMBL27302588 0.76 LMNA (0.44) ELOVL1LMNASMN1; SMN2PIK3CDEGLN1
SCHEMBL17229321 0.73 ACACB (0.48) ACACB
SCHEMBL8245690 0.72 KCNH2 (0.38) LMNA
SCHEMBL14349672 0.71 LMNA (0.45) ELOVL1ACACBLMNASMN1; SMN2PIK3CD
SCHEMBL24198823 0.70 PDE10A (0.36) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695166-B2 Pyrazolopyridine pyrazolopyrimidine and related compounds GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-07-04 US disclosed
US-9695166-B2 Pyrazolopyridine pyrazolopyrimidine and related compounds GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-07-04 US disclosed
WO-2015171527-A1 PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2015-11-12 WO disclosed
US-20150315198-A1 PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2015-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315198-A1 PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS TPMT, DPYD, XDH ELOVL1 4792/4885ACACB 3142/4885LMNA 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.